These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 23991844)

  • 1. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
    J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.
    Tamura K; Aoyagi M; Wakimoto H; Ando N; Nariai T; Yamamoto M; Ohno K
    J Neurosurg; 2010 Aug; 113(2):310-8. PubMed ID: 20205512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
    Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
    Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
    Li MW; Niu CS
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
    Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
    Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
    Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
    Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
    BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133-positive stem cells.
    Bian EB; Li J; Zhao B
    J Neurosurg; 2014 Apr; 120(4):1011-2. PubMed ID: 24506246
    [No Abstract]   [Full Text] [Related]  

  • 16. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity.
    Zhang B; Sun J; Yu SP; Chen C; Liu B; Liu ZF; Ren BC; Ming HL; Yang XJ
    Chin Med J (Engl); 2012 Dec; 125(24):4344-8. PubMed ID: 23253699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133-positive stem cells. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1012. PubMed ID: 24809085
    [No Abstract]   [Full Text] [Related]  

  • 18. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.
    Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP
    Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of PKCδ signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment.
    Kim MJ; Kim RK; Yoon CH; An S; Hwang SG; Suh Y; Park MJ; Chung HY; Kim IG; Lee SJ
    J Cell Sci; 2011 Sep; 124(Pt 18):3084-94. PubMed ID: 21878493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.